151 related articles for article (PubMed ID: 19036912)
1. Estimating the prevalence of ex-injecting drug use in the population.
Sweeting M; De Angelis D; Ades A; Hickman M
Stat Methods Med Res; 2009 Aug; 18(4):381-95. PubMed ID: 19036912
[TBL] [Abstract][Full Text] [Related]
2. Estimating the variability in the risk of infection for hepatitis C in the Glasgow injecting drug user population.
Sutton AJ; McDonald SA; Palmateer N; Taylor A; Hutchinson SJ
Epidemiol Infect; 2012 Dec; 140(12):2190-8. PubMed ID: 22459739
[TBL] [Abstract][Full Text] [Related]
3. Estimating hepatitis C prevalence in England and Wales by synthesizing evidence from multiple data sources. Assessing data conflict and model fit.
Sweeting MJ; De Angelis D; Hickman M; Ades AE
Biostatistics; 2008 Oct; 9(4):715-34. PubMed ID: 18349037
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C virus acquisition among injecting drug users: a cohort analysis of a national repeated cross-sectional survey of needle and syringe program attendees in Australia, 1995-2004.
Falster K; Kaldor JM; Maher L;
J Urban Health; 2009 Jan; 86(1):106-18. PubMed ID: 18979201
[TBL] [Abstract][Full Text] [Related]
5. Estimating the prevalence of injection drug users in the U.S. and in large U.S. metropolitan areas from 1992 to 2002.
Brady JE; Friedman SR; Cooper HL; Flom PL; Tempalski B; Gostnell K
J Urban Health; 2008 May; 85(3):323-51. PubMed ID: 18344002
[TBL] [Abstract][Full Text] [Related]
6. Modelling HIV in the injecting drug user population and the male homosexual population in a developed country context.
Sutton AJ; House T; Hope VD; Ncube F; Wiessing L; Kretzschmar M
Epidemics; 2012 Mar; 4(1):48-56. PubMed ID: 22325014
[TBL] [Abstract][Full Text] [Related]
7. A Bayesian evidence synthesis approach to estimate disease prevalence in hard-to-reach populations: hepatitis C in New York City.
Tan S; Makela S; Heller D; Konty K; Balter S; Zheng T; Stark JH
Epidemics; 2018 Jun; 23():96-109. PubMed ID: 29666018
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for hepatitis C virus infection among injecting drug users in Sydney.
van Beek I; Buckley R; Stewart M; MacDonald M; Kaldor J
Genitourin Med; 1994 Oct; 70(5):321-4. PubMed ID: 8001943
[TBL] [Abstract][Full Text] [Related]
9. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales.
Sutton AJ; Gay NJ; Edmunds WJ; Hope VD; Gill ON; Hickman M
BMC Infect Dis; 2006 Jun; 6():93. PubMed ID: 16762050
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and incidence of hepatitis C in injecting drug users attending genitourinary medicine clinics.
Balogun MA; Murphy N; Nunn S; Grant A; Andrews NJ; Teo CG; Ramsay ME; Parry JV
Epidemiol Infect; 2009 Jul; 137(7):980-7. PubMed ID: 19102796
[TBL] [Abstract][Full Text] [Related]
11. Improving survey methods in sero-epidemiological studies of injecting drug users: a case example of two cross sectional surveys in Serbia and Montenegro.
Judd A; Rhodes T; Johnston LG; Platt L; Andjelkovic V; Simić D; Mugosa B; Simić M; Zerjav S; Parry RP; Parry JV
BMC Infect Dis; 2009 Feb; 9():14. PubMed ID: 19203380
[TBL] [Abstract][Full Text] [Related]
12. Is the HCV-HIV co-infection prevalence amongst injecting drug users a marker for the level of sexual and injection related HIV transmission?
Vickerman P; Martin NK; Roy A; Beattie T; Jarlais DD; Strathdee S; Wiessing L; Hickman M;
Drug Alcohol Depend; 2013 Sep; 132(1-2):172-81. PubMed ID: 23453261
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and genotypes of hepatitis C virus among injecting drug users from Salvador-BA, Brazil.
Silva MB; Andrade TM; Silva LK; Rodart IF; Lopes GB; Carmo TM; Zarife MA; Dourado I; Reis MG
Mem Inst Oswaldo Cruz; 2010 May; 105(3):299-303. PubMed ID: 20512243
[TBL] [Abstract][Full Text] [Related]
14. Seroprevalence of blood-borne infections and population sizes estimates in a population of injecting drug users in Croatia.
Kolarić B; Stajduhar D; Gajnik D; Rukavina T; Wiessing L
Cent Eur J Public Health; 2010 Jun; 18(2):104-9. PubMed ID: 20939261
[TBL] [Abstract][Full Text] [Related]
15. Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK. Part 1: Critical hepatitis C and injector data.
Bird SM; Goldberg DJ; Hutchinson SJ
J Epidemiol Biostat; 2001; 6(3):243-65; discussion 279-85. PubMed ID: 11437088
[TBL] [Abstract][Full Text] [Related]
16. HIV and hepatitis C virus risk in new and longer-term injecting drug users in Oslo, Norway.
Miller M; Mella I; Moi H; Eskild A
J Acquir Immune Defic Syndr; 2003 Jul; 33(3):373-9. PubMed ID: 12843749
[TBL] [Abstract][Full Text] [Related]
17. Mathematically modelling the spread of hepatitis C in injecting drug users.
Corson S; Greenhalgh D; Hutchinson S
Math Med Biol; 2012 Sep; 29(3):205-30. PubMed ID: 21900152
[TBL] [Abstract][Full Text] [Related]
18. Population-based prevalence of hepatitis B and C virus, HIV, syphilis, gonorrhoea and chlamydia in male injection drug users in Lagos, Nigeria.
Tun W; Vu L; Adebajo SB; Abiodun L; Sheehy M; Karlyn A; Njab J; Ahonsi B; Issa BK; Idogho O
Int J STD AIDS; 2013 Aug; 24(8):619-25. PubMed ID: 23970571
[TBL] [Abstract][Full Text] [Related]
19. Low knowledge and perceived Hepatitis C risk despite high risk behaviour among injection drug users in Kathmandu, Nepal.
Loewinger G; Sharma B; Karki DK; Khatiwoda P; Kainee S; Poudel KC
Int J Drug Policy; 2016 Jul; 33():75-82. PubMed ID: 27318773
[TBL] [Abstract][Full Text] [Related]
20. Predictors of hepatitis B and C infection in injecting drug users both in and out of drug treatment.
Cook PA; McVeigh J; Syed Q; Mutton K; Bellis MA
Addiction; 2001 Dec; 96(12):1787-97. PubMed ID: 11784471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
